ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Emulated Target Trials and Phenotyping in Patients with Acute Respiratory Distress Syndrome

Active
Institution
Massachusetts Institute of Technology, MA
Principal investigator
Li-Wei H Lehman
Funding
$1.5M
Duration
2025–2027
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY/ABSTRACT Acute respiratory distress syndrome (ARDS) is a severe form of lung injury with significant public health implications due to severe morbidity and mortality. The need to utilize existing data to inform prospective research and clinical decision making was emphasized during the COVID pandemic, when ARDS became a leading cause of death, and clinicians were forced to operate outside of existing evidence. Many commonly applied interventions including use of neuromuscular blockade (NMB), steroids, driving pressure and mechanical power are used despite negative data, without high quality prospective studies or with equivocal evidence and with the potential for both benefit or harm. Additionally, phenotypes of ARDS may have different prognosis and response to treatment, but thus far have not been well differentiated using routinely available dynamic clinical data, nor have they been incorporated into prospective trials. ‘Dynamic treatment regimes’ (DTRs) are rules for making treatment decisions sequentially at multiple time-points based on a patient’s evolving history. Most relevant treatment strategies for ARDS are DTRs. DTRs may be evaluated in randomized trials, however it is infeasible to conduct randomized trials testing all DTRs of interest. This grant proposes ‘target trial emulation’ from observational data using ‘g-methods’ for confounding adjustment to address multiple gaps in our knowledge about ARDS care. We will address important methodological gaps in ARDS phenotyping and develop advanced machine learning (ML) methods for dynamic phenotyping for prognostication and personalized DTRs to determine for whom and when specific ARDS treatments are beneficial. The investigation will utilize three large datasets—including the Medical Information Mart for Intensive Care (MIMIC) IV database, the eICU collaborative research database, and the Dutch AmsterdamUMCdb database—representing a wide geographic and demographic spectrum, and the ability to assess stability of findings across geography and centers. To address these knowledge gaps regarding use of NMB, steroids, driving pressure and mechanical power, as well as identify phenotypes of patients most responsive to treatment, we propose two overarching aims for this grant. Specific Aim 1) Using target trial emulations and g-methods, we will estimate clinical outcomes that would result under a range of treatment strategies for NMB, steroids as well as driving pressure and mechanical power thresholds. Specific Aim 2) We will develop machine learning methods to derive dynamic markers for ARDS phenotyping and formulate personalized DTRs for ARDS treatment. The project represents a collaborative effort between experts in critical care medicine (with a specialty in mechanical ventilation), machine learning, and causal inference. Our results will address important gaps in clinical knowledge about treatment of ARDS and inform the design of future randomized trials. Our study designs, code, and constructed cohorts will also provide valuable templates for other researchers to use in future observational studies, which we foresee will broadly improve the quality of evidence from observational data in critical care.

Research team

  • Elias Baedorf KassisPI
  • Li-Wei H LehmanPI
  • Zachary ShahnPI

LOADING MOONBASE SCORE

NATIONAL HEART, LUNG, AND BLOOD INSTITUTER01Special Emphasis Panel[ZRG1 HSS-Y (90)]steroidsphenotypingobservational datarespiratory distressardsdistress syndromerandomized trialscritical care

Questions for Massachusetts Institute of Technology

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.